{
  "abstract": "Patient-specific tumor heterogeneity limits the efficacy of conventional T-cell immunotherapies. We report MATCH, a modular split-antibody T-cell engager platform, and COMPASS, a computational framework that predicts individualized multi-specific therapy compositions. COMPASS integrates T-cell counts, tumor burden, and antigen expression (CD19, CD20, CD38) to identify dose combinations that maximize tumor cell killing while preserving T-cell viability. COMPASS accurately predicted effective multi-specific formulations for chronic lymphocytic leukemia patient PBMC samples and successfully predicted compositions to treat a human lymphoma xenograft murine model that led to significantly improved survival. This lab-in-the-loop experimental-computational approach provides a generalizable blueprint for precision T-cell immunotherapy and offers a new paradigm in patient-specific cancer treatment.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Biomedical Engineering, University of Utah, Salt Lake City, UT USA",
    "Huntsman Cancer Institute, University of Utah, Salt Lake City, UT USA",
    "Department of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT USA",
    "U2TAH Therapeutics Accelerator, University of Utah, Salt Lake City, UT USA",
    "Department of Statistics, Brigham Young University, Provo, UT USA"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 10,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Isaac Kendell"
    },
    {
      "affs": [
        1
      ],
      "name": "Richard McShinsky"
    },
    {
      "affs": [
        1
      ],
      "name": "Katarzyna Modzelewska"
    },
    {
      "affs": [
        2
      ],
      "name": "Lauren Naatz"
    },
    {
      "affs": [
        3
      ],
      "name": "Alex Stark"
    },
    {
      "affs": [
        3
      ],
      "name": "David Bearss"
    },
    {
      "affs": [
        4
      ],
      "name": "Jeffry Troll"
    },
    {
      "affs": [
        1
      ],
      "name": "Douglas Sborov",
      "orcid": "0000-0003-4268-2698"
    },
    {
      "affs": [
        2
      ],
      "name": "Shawn Owen",
      "orcid": "0000-0001-5996-7679"
    },
    {
      "affs": [
        2
      ],
      "name": "M. Tommy Gambles",
      "orcid": "0000-0003-0461-4926"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/5xdmveyk4tdgc.bib",
  "cited_by": 0,
  "doi": "10.1038/s42003-026-10602-4",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13737095/",
  "id": "5xdmveyk4tdgc",
  "issns": [
    "2399-3642"
  ],
  "landing_url": "https://doi.org/10.1038/s42003-026-10602-4",
  "language": "en",
  "licence": "CC-BY-NC-ND-4.0",
  "licence_label": "CC BY-NC-ND 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Article"
    ],
    [
      "openalex",
      "2730|CAR-T cell therapy research"
    ]
  ],
  "openalex": "W7168131556",
  "pdf_url": null,
  "pmcid": "PMC13737095",
  "pmid": "42443393",
  "published": "2026-07-13",
  "publisher": "Nature Publishing Group",
  "ris": "https://research.draconitic.com/paper/5xdmveyk4tdgc.ris",
  "sources": [
    {
      "first_seen": "2026-11-09T12:22:23Z",
      "native_id": "PMC13737095",
      "source": "pmc",
      "url": "https://doi.org/10.1038/s42003-026-10602-4"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|CAR-T cell therapy research",
      "subfield": "oncology"
    }
  ],
  "title": "Computer-guided dosing of multi-specific T-cell engagers",
  "title_text": "Computer-guided dosing of multi-specific T-cell engagers",
  "type": "peer-reviewed",
  "updated_at": "2026-11-09T12:22:23Z",
  "url": "https://research.draconitic.com/paper/5xdmveyk4tdgc",
  "venue": "Communications Biology",
  "versions": []
}